2023
DOI: 10.1097/01.hs9.0000968852.56785.3a
|View full text |Cite
|
Sign up to set email alerts
|

P486: REAL-WORLD EFFECTIVENESS AND SAFETY OF CPX-351 IN PATIENTS AGED <60 AND ≥60 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: CREST-UK POST-HOC ANALYSIS

Abstract: Favorable survival outcomes with CPX-351 vs conventional 7+3 and comparable safety in adults aged 60-75 years in the pivotal phase 3 trial (NCT01696084) led to the approval of CPX-351 for newly diagnosed therapy-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (AML MRC) in the US and Europe. However, the trial did not include patients aged <60 years, creating a data gap on the potential effectiveness in younger patients. The CPX-351 Real-world Effectiveness and SafeTy (CREST-UK;… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles